Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)

被引：0
|
作者：
McGuire, WP
Hoskins, WJ
Brady, MF
Kucera, PR
Partridge, EE
Look, KY
ClarkePearson, DL
Davidson, M
机构：
[1] EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA
[2] MEM SLOAN KETTERING CANC CTR, DEPT SURG, GYNECOL SERV, NEW YORK, NY 10021 USA
[3] CORNELL UNIV, COLL MED, DEPT OBSTET & GYNECOL, NEW YORK, NY USA
[4] ROSWELL PK CANC INST, GYNECOL ONCOL GRP, STAT OFF, BUFFALO, NY USA
[5] OREGON HLTH SCI UNIV, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, PORTLAND, OR 97201 USA
[6] UNIV ALABAMA, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, BIRMINGHAM, AL 35294 USA
[7] INDIANA UNIV, SCH MED, DIV OBSTET & GYNECOL, INDIANAPOLIS, IN USA
[8] DUKE UNIV, SCH MED, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, DURHAM, NC 27706 USA
[9] WALTER REED ARMY MED CTR, DEPT PATHOL & AREA LAB SCI, WASHINGTON, DC 20307 USA
来源：
SEMINARS IN ONCOLOGY | 1996年 / 23卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：40 / 47
页数：8
相关论文
共 50 条
  • [1] Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study
    Muggia, FM
    Braly, PS
    Brady, MF
    Sutton, G
    Niemann, TH
    Lentz, SL
    Alvarez, RD
    Kucera, PR
    Small, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 106 - 115
  • [2] Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: A gynecologic oncology group study
    McGuire, WP
    Hoskins, WJ
    Brady, MF
    Kucera, PR
    Partridge, EE
    Look, KY
    ClarkPearson, DL
    Davidson, M
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [3] Comparison of combination therapy with paclitaxel Taxol(R) and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: A Gynecologic Oncology Group study
    McGuire, WP
    Hoskins, WJ
    Brady, MF
    Kucera, PR
    Partridge, EE
    Look, KY
    ClarkePearson, DL
    Davidson, M
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 : 2 - 8
  • [4] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    McGuire, WP
    Hoskins, WJ
    Brady, MF
    Kucera, PR
    Partridge, EE
    Look, KY
    ClarkePearson, DL
    Davidson, M
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01): : 1 - 6
  • [5] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
    Ozols, RF
    Bundy, BN
    Greer, BE
    Fowler, JM
    Clarke-Pearson, D
    Burger, RA
    Mannel, RS
    DeGeest, K
    Hartenbach, EM
    Baergen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3194 - 3200
  • [6] Phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer
    Mouratidou, D.
    Gennatas, C.
    Michalaki, V.
    Papadimitriou, A.
    Andreadis, Ch.
    Sykiotis, C.
    Tsavaris, N.
    ANTICANCER RESEARCH, 2007, 27 (1B) : 681 - 685
  • [7] Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg
    Wils, J
    van Geuns, H
    Stoot, J
    Bergmans, M
    Boschma, F
    Bron, H
    Degen, J
    Erdkamp, F
    van Erp, J
    Haest, J
    Iding, R
    Lalisang, F
    de Pree, N
    de Rooy, C
    Snijders, M
    Schepers, J
    Vreeswijk, J
    Wals, J
    Werter, M
    Wetzels, L
    Smeets, J
    Schouten, L
    ANTI-CANCER DRUGS, 1999, 10 (03) : 257 - 261
  • [8] A RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN WITH OR WITHOUT BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUBOPTIMAL STAGE-III AND STAGE-IV OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    CREASMAN, WT
    OMURA, GA
    BRADY, MF
    YORDAN, E
    DISAIA, PJ
    BEECHAM, J
    GYNECOLOGIC ONCOLOGY, 1990, 39 (03) : 239 - 243
  • [9] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer (vol 334, pg 1, 1996)
    McGuire, WP
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16): : 1070 - 1070
  • [10] Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial.
    Wenzel, LB
    Huang, H
    Armstrong, D
    Walker, J
    Cella, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 455S - 455S
12345